University of Crete   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Rethymno Greece (1973)

Organization Overview

First Clinical Trial
2001
NCT00424606
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Gastroenterology, University Hospital of Heraklion, University of Crete, Heraklion, Greece | University Hospital of Crete | University Hospital of Crete, Department of Medical Oncology | University Hospital of Crete, Dep of Medical Oncology | University Hospital of Crete, Dept. of Medical Oncology | University Hospital of Heraklion | University Hospital of Heraklion, Crete | University Hospital of Heraklion Dept. of Medical Oncology | University Hospital of Herklion | University of Crete | University of Crete, Medical School

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Fever (Phase 4)

Lung Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 62
  • # of Trial APIs: 34